Immunovia AB (publ) IMMNOV
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Wait/hold a small watch position until clear volume growth and improved coverage signals emerge.
The Q2 report confirms low revenue growth and high burn rate, keeping the signal at review until clear signs of Medicare progress and volume growth appear.
Sentiment has improved to more neutral following published AFFIRM results and new performance data that strengthen the reimbursement narrative, yet the market remains focused on low revenue, funding needs and US execution risk.
NEUTRAL is the call. Neutral is the market mood. High risk means a lot can go wrong.
Latest change
- 7 Aug 2026 — The report confirms low revenue and high burn, increasing focus on financing needs.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (4) — follow the company freeAbout the company
Immunovia AB (publ) develops and commercializes PancreaSure, a blood test aimed at early detection of pancreatic cancer in high-risk patients. The company is in an early U.S. commercialization phase with very low revenues and continued cash burn. Key value drivers are reimbursement/coverage, state-by-state regulatory rollout, and clinical utility evidence.
Bull case
Confirmed Medicare submission could rapidly broaden sales and trigger a price reaction from the low valuation.
Bear case
Lack of Medicare submission news combined with a dwindling cash position risks heightening funding concerns.
Why this signal
The Q2 report confirms low revenue growth and high burn rate, keeping the signal at review until clear signs of Medicare progress and volume growth appear.
Recent news
A patient survey published on 13 August shows over 90 % of high-risk patients prefer blood-based tests such as PancreaSure. The share price has declined to 0.1296 SEK with continued focus on cash runway.